Last updated on January 2019

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib Docetaxel or Enzalutamide in Metastatic Castration-resistant Prostate Cancer


Brief description of study

The purpose of this study is to assess the safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.

Clinical Study Identifier: NCT03338790

Find a site near you

Start Over

Southern Cancer Center Pc

Daphne, AL United States
  Connect »

Local Institution

San Francisco, CA United States
  Connect »

Local Institution

Belo Horizonte, Brazil
  Connect »

Local Institution

Porto Alegre, Brazil
  Connect »

Local Institution

Rio de Janeiro, Brazil
  Connect »

Local Institution

Santa Catarina, Brazil
  Connect »

Local Institution

Edmonton, AB Canada
  Connect »

Local Institution

Vancouver, BC Canada
  Connect »

Local Institution

Saint John, NB Canada
  Connect »

Local Institution

Clermont-ferrand, France
  Connect »

Local Institution

Guadalajara, Mexico
  Connect »

Local Institution

Boston, MA United States
  Connect »

Local Institution

Minneapolis, MN United States
  Connect »

Lehigh Valley Health Network

Allentown, PA United States
  Connect »

Westmead Hospital

Westmead, Australia
  Connect »

Austin Hospital

Heidelberg, Australia
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »

Duke University

Durham, NC United States
  Connect »

Hospital Britanico De Buenos Aires

Ciudad Autonoma de Buenos Aires, Argentina
  Connect »

Tulane University

New Orleans, LA United States
  Connect »

Karmanos Cancer Center

Detroit, MI United States
  Connect »

ICON Cancer Center

South Brisbane, Australia
  Connect »

Lyell McEwin Hospital

Elizabeth Vale, Australia
  Connect »